Updates on Clinical Trials in Systemic Lupus Erythematosus

被引：4

作者：

Sharabi, Amir ^{[1
,2
]}

机构：

[1] Rabin Med Ctr, Rheumatol Inst, Petah Tiqwa, Israel

[2] Tel Aviv Univ, Sackler Fac Med, Microbiol & Immunol Dept, Tel Aviv, Israel

来源：

CURRENT RHEUMATOLOGY REPORTS | 2021年 / 23卷 / 07期

关键词：

Systemic lupus erythematosus (SLE); Clinical trials; Treatment; Immunosuppression; DOUBLE-BLIND; NEPHRITIS; ATACICEPT; EFFICACY; SAFETY; TARGET;

D O I：

10.1007/s11926-021-01014-w

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose of Review Because of the complexity of systemic lupus erythematosus (SLE), different approaches are undertaken while investigating potential therapeutic compounds to treat the disease. The purpose of this review is to summarize the results from recent clinical trials, which investigated different compounds for treating SLE. Recent Findings Targeting B cells and type I interferons constitutes the major focus in recent clinical trials. The potential for therapeutic effects of small molecule inhibition such as JAK, Tyk, and Btk is now being investigated for treating SLE. The immunoregulation of T cell activation in SLE is studied using low-dose IL-2 and CD40 ligand inhibition. There are clinical trials that study bispecific antibodies, with binding specificities for 2 different target molecules related to T- and B-cell activation or to different aspects of B cell activation. An approach of combination treatment is also being studied. Clinical trials are underway and new treatment compounds for SLE are being anticipated.

引用

页数：8

共 22 条

[1] PREDICTING RENAL OUTCOMES IN SEVERE LUPUS NEPHRITIS - CONTRIBUTIONS OF CLINICAL AND HISTOLOGIC DATA [J].

AUSTIN, HA ;

BOUMPAS, DT ;

VAUGHAN, EM ;

BALOW, JE .

KIDNEY INTERNATIONAL, 1994, 45 (02) :544-550

[2] Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator [J].

Baker, KP ;

Edwards, BM ;

Main, SH ;

Choi, GH ;

Wager, RE ;

Halpern, WG ;

Lappin, PB ;

Riccobene, T ;

Abramian, D ;

Sekut, L ;

Sturm, B ;

Poortman, C ;

Minter, RR ;

Dobson, CL ;

Williams, E ;

Carmen, S ;

Smith, R ;

Roschke, V ;

Hilbert, DM ;

Vaughan, TJ ;

Albert, VR .

ARTHRITIS AND RHEUMATISM, 2003, 48 (11) :3253-3265

[3] Identification of Biomarkers That Predict Response to Treatment of Lupus Nephritis With Mycophenolate Mofetil or Pulse Cyclophosphamide [J].

Dall'Era, Maria ;

Stone, David ;

Levesque, Victoria ;

Cisternas, Miriam ;

Wofsy, David .

ARTHRITIS CARE & RESEARCH, 2011, 63 (03) :351-357

[4] Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis [J].

Furie, Richard ;

Rovin, Brad H. ;

Houssiau, Frederic ;

Malvar, Ana ;

Teng, Y. K. Onno ;

Contreras, Gabriel ;

Amoura, Zahir ;

Yu, Xueqing ;

Mok, Chi-Chiu ;

Santiago, Mittermayer B. ;

Saxena, Amit ;

Green, Yulia ;

Ji, Beulah ;

Kleoudis, Christi ;

Burriss, Susan W. ;

Barnett, Carly ;

Roth, David A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (12) :1117-1128

[5] Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial [J].

He, Jing ;

Zhang, Ruijun ;

Shao, Miao ;

Zhao, Xiaozhen ;

Miao, Miao ;

Chen, Jiali ;

Liu, Jiajia ;

Zhang, Xiaoying ;

Zhang, Xia ;

Jin, Yuebo ;

Wang, Yu ;

Zhang, Shilei ;

Zhu, Lei ;

Jacob, Alexander ;

Jia, Rulin ;

You, Xujie ;

Li, Xue ;

Li, Chun ;

Zhou, Yunshan ;

Yang, Yue ;

Ye, Hua ;

Liu, Yanying ;

Su, Yin ;

Shen, Nan ;

Alexander, Jessy ;

Guo, Jianping ;

Ambrus, Julian ;

Lin, Xin ;

Yu, Di ;

Sun, Xiaolin ;

Li, Zhanguo .

ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (01) :141-149

[6] IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study [J].

Houssiau, Frederic A. ;

Thanou, Aikaterini ;

Mazur, Minodora ;

Ramiterre, Edgar ;

Gomez Mora, Danny Alexis ;

Misterska-Skora, Maria ;

Alfredo Perich-Campos, Risto ;

Smakotina, Svetlana A. ;

Cerpa Cruz, Sergio ;

Louzir, Bassem ;

Croughs, Therese ;

Lucas Tee, Michael .

ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (03) :347-355

[7] CALCINEURIN IS A COMMON TARGET OF CYCLOPHILIN-CYCLOSPORINE-A AND FKBP-FK506 COMPLEXES [J].

LIU, J ;

FARMER, JD ;

LANE, WS ;

FRIEDMAN, J ;

WEISSMAN, I ;

SCHREIBER, SL .

CELL, 1991, 66 (04) :807-815

[8] Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study [J].

Merrill, Joan T. ;

Wallace, Daniel J. ;

Wax, Stephen ;

Kao, Amy ;

Fraser, Patricia A. ;

Chang, Peter ;

Isenberg, David .

ARTHRITIS & RHEUMATOLOGY, 2018, 70 (02) :266-276

[9] Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis [J].

Mok, Chi Chiu ;

Ho, Ling Yin ;

Ying, Shirley King Yee ;

Leung, Man Chi ;

To, Chi Hung ;

Ng, Woon Leung .

ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (08) :1070-1076

[10] Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up [J].

Mok, Chi Chiu ;

Ying, King Yee ;

Yim, Cheuk Wan ;

Siu, Yui Pong ;

Tong, Ka Hang ;

To, Chi Hung ;

Ng, Woon Leung .

ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (01) :30-36

← 1 2 3 →